These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23895115)

  • 1. Detection of low-frequency HIV type 1 reverse transcriptase drug resistance mutations by ultradeep sequencing in naive HIV type 1-infected individuals.
    Bellecave P; Recordon-Pinson P; Papuchon J; Vandenhende MA; Reigadas S; Tauzin B; Fleury H
    AIDS Res Hum Retroviruses; 2014 Feb; 30(2):170-3. PubMed ID: 23895115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
    Nicot F; Saliou A; Raymond S; Sauné K; Dubois M; Massip P; Marchou B; Delobel P; Izopet J
    J Clin Virol; 2012 Oct; 55(2):107-13. PubMed ID: 22818969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing.
    Alteri C; Santoro MM; Abbate I; Rozera G; Bruselles A; Bartolini B; Gori C; Forbici F; Orchi N; Tozzi V; Palamara G; Antinori A; Narciso P; Girardi E; Svicher V; Ceccherini-Silberstein F; Capobianchi MR; Perno CF
    J Antimicrob Chemother; 2011 Nov; 66(11):2615-23. PubMed ID: 21890537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.
    Pattery T; Verlinden Y; De Wolf H; Nauwelaers D; Van Baelen K; Van Houtte M; Mc Kenna P; Villacian J
    Intervirology; 2012; 55(2):138-46. PubMed ID: 22286884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naive patients.
    Messiaen P; Verhofstede C; Vandenbroucke I; Dinakis S; Van Eygen V; Thys K; Winters B; Aerssens J; Vogelaers D; Stuyver LJ; Vandekerckhove L
    Virology; 2012 Apr; 426(1):7-11. PubMed ID: 22305619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing.
    Simen BB; Braverman MS; Abbate I; Aerssens J; Bidet Y; Bouchez O; Gabriel C; Izopet J; Kessler HH; Stelzl E; Di Giallonardo F; Schlapbach R; Radonic A; Paredes R; Recordon-Pinson P; Sakwa J; St John EP; Schmitz-Agheguian GG; Metzner KJ; Däumer MP;
    J Virol Methods; 2014 Aug; 204():31-7. PubMed ID: 24731928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detecting primary drug-resistant mutations in Korean HIV patients using ultradeep pyrosequencing.
    Cho MC; Park CW; Park BG; Oh HB; Choi SH; Choi SE; Cho NS
    J Virol Methods; 2016 Aug; 234():115-22. PubMed ID: 27109046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.
    Kozal MJ; Chiarella J; St John EP; Moreno EA; Simen BB; Arnold TE; Lataillade M
    Antivir Ther; 2011; 16(6):925-9. PubMed ID: 21900725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained appearance of drug resistance-associated mutations in HIV-1 CRF01_AE protease and reverse transcriptase derived from protease inhibitor-naive Thai patients.
    Jullaksorn D; Boonchawalit S; Uttiyoung J; Soonthornsata B; Yowang A; Krathong N; Chautrakul S; Ikuta K; Roobsoong A; Kanitvittaya S; Sawanpanyalert P; Kameoka M
    Southeast Asian J Trop Med Public Health; 2010 Mar; 41(2):347-57. PubMed ID: 20578518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.
    Saracino A; Monno L; Scudeller L; Cibelli DC; Tartaglia A; Punzi G; Torti C; Lo Caputo S; Mazzotta F; Scotto G; Carosi G; Angarano G
    J Med Virol; 2006 Jan; 78(1):9-17. PubMed ID: 16299731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations.
    Mitsuya Y; Varghese V; Wang C; Liu TF; Holmes SP; Jayakumar P; Gharizadeh B; Ronaghi M; Klein D; Fessel WJ; Shafer RW
    J Virol; 2008 Nov; 82(21):10747-55. PubMed ID: 18715933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fast genotypic detection of drug resistance mutations in the HIV-1 reverse transcriptase gene of treatment-naive patients.
    Fontaine E; Lambert C; Servais J; Ninove D; Plesséria JM; Staub T; Arendt V; Kirpach P; Robert I; Schneider F; Hemmer R; Schmit JC
    J Hum Virol; 1998; 1(7):451-6. PubMed ID: 10195266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Automatic Analysis of Ultradeep Pyrosequencing Raw Data to Determine Percentages of HIV Resistance Mutations in Patients Followed-Up in Hospital.
    Bellecave P; Recordon-Pinson P; Fleury H
    AIDS Res Hum Retroviruses; 2016 Jan; 32(1):85-92. PubMed ID: 26529549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
    Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
    HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation.
    Delaugerre C; Flandre P; Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Schneider V; Yerly S; LeGoff J; Morand-Joubert L; Chaix ML; Costagliola D; Calvez V;
    J Med Virol; 2008 May; 80(5):762-5. PubMed ID: 18360911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of protease and reverse transcriptase drug resistance mutations in naïve HIV-infected patients.
    Valle-Bahena OM; Ramos-Jiménez J; Ortiz-López R; Revol A; Lugo-Trampe A; Barrera-Saldaña HA; Rojas-Martínez A
    Arch Med Res; 2006 Nov; 37(8):1022-7. PubMed ID: 17045121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation covariation of HIV-1 CRF07_BC reverse transcriptase during antiretroviral therapy.
    Li Z; Huang Y; Ouyang Y; Xing H; Liao L; Jiang S; Shao Y; Ma L
    J Antimicrob Chemother; 2013 Nov; 68(11):2521-4. PubMed ID: 23788482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitive detection of the K103N non-nucleoside reverse transcriptase inhibitor resistance mutation in treatment-naïve HIV-1 infected individuals by rolling circle amplification.
    Wang B; Dwyer DE; Chew CB; Kol C; He ZP; Joshi H; Steain MC; Cunningham AL; Saksena NK
    J Virol Methods; 2009 Oct; 161(1):128-35. PubMed ID: 19523982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.